Search Videos and More

Showing 1 - 12 of 37 results

Previous| 1 | 2 | 3 ...4 |Next


Antibody-Drug Conjugates: A Cancer Therapy Revolution News

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients
Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer Document

Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction News

Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction

Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer News

Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer

A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
Treatment Guidelines: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer Document

Treatment Guidelines: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD Video

ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD

Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD Video

ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD

Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD Video

ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD

Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing News

New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.
Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer News

Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer

Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic HR+, HER2- breast cancer.
SABCS 2022: Sara Tolaney, MD, MPH Video

SABCS 2022: Sara Tolaney, MD, MPH

Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and trastuzumab confirm excellent long-term outcomes for small, node-negative HER2-positive breast cancer.
SABCS 2022: Paolo Tarantino, MD Video

SABCS 2022: Paolo Tarantino, MD

ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.

Showing 1 - 12 of 37 results

Previous| 1 | 2 | 3 ...4 |Next